Navigation Links
Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial
Date:8/10/2009

PALO ALTO, Calif., Aug. 10, 2009 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today that the first patients have been dosed in an innovative clinical trial in patients chronically infected with the hepatitis C virus (HCV). The trial, run in centers in Australia and New Zealand, will investigate the antiviral effect of clemizole monotherapy in the absence of interferon.

CLEAN-1 will evaluate the safety and antiviral activity of clemizole, a first generation antihistamine, in 28 days of oral therapy in treatment-naive patients infected with HCV genotypes 1 and 2. This direct antiviral study represents an important first step in evaluating the therapeutic potential of inhibiting a new target in HCV -- small molecule inhibition of the interaction between NS4B and HCV-RNA that is required for HCV replication.

"This proof of concept study is an important first step in our comprehensive development strategy for clemizole and newly discovered NS4B-RNA binding inhibitors for the treatment of HCV," said David Cory, President and CEO of Eiger. "Inhibiting the NS4B-RNA interaction represents an exciting new approach toward developing interferon-free, virus-specific agents to treat HCV."

Eiger BioPharmaceuticals recently announced the acquisition of the exclusive license to this novel HCV technology, discovered in the labs of Stanford scientist and Eiger Founder, Dr. Jeffrey Glenn, M.D., Ph.D. and colleagues. Clemizole targets a non-structural protein found in the HCV genome, NS4B, which binds to HCV-RNA and is required for virus replication. Disrupting the function of this protein represents a new approach to treat HCV infection and may be associated with less drug resistance than polymerase and protease inhibitors in development.

About NS4B and Clemiz
'/>"/>

SOURCE Eiger BioPharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
2. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
3. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
4. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
5. XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
6. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
7. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
8. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
9. XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
10. Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis
11. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)...  ViewRay™, a privately held medical device company, announced today ... with ITOCHU Corporation (Tokyo Stock Exchange TYO: 8001) to ... of cancer in Japan . ViewRay,s ... and only MRI-guided radiation therapy system that images and ...
(Date:1/22/2015)... Inc. (NASDAQ: UPI ), a medical device company ... treat voiding dysfunctions, today reported financial results for the ... Global revenue for the Company,s Urgent ®  PC Neuromodulation ... revenue record, as compared to $3.9 million in the ...
(Date:1/22/2015)... /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), ... for cardiovascular disease and overall health is pleased to provide ... and its outlook for 2015 from the CEO, Mr. ... We would like to take this opportunity to share with ...
Breaking Medicine Technology:ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... Fla. , July 6 Biotechnology pioneer Divine Skin ... consumer health-care division to capitalize on the pharmaceutical research it has ... skin. The new division will target both over-the-counter and prescription drug ... In ...
... Reportlinker.com announces that a new market research report is available in its ... European Markets for Gastrointestinal Endoscopic ... , http://www.reportlinker.com/p0196554/European-Markets-for-Gastrointestinal-Endoscopic-Devices-2010-15-Countries.html ... The European market for gastrointestinal endoscopic ...
Cached Medicine Technology:Divine Skin (DSKX) Launches Health-Care Division To Develop New OTC and Prescription Drugs 2Divine Skin (DSKX) Launches Health-Care Division To Develop New OTC and Prescription Drugs 3Divine Skin (DSKX) Launches Health-Care Division To Develop New OTC and Prescription Drugs 4Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 2Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 3Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 4Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 5Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 6Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 7Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 8Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 9Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 10Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 11Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 12Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 13Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 14Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 15Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 16Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 17Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 18Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 19Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 20Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 21Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 22Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 23Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 24Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 25Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 26Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 27Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 28Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 29Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 30Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 31Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 32Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 33
(Date:1/22/2015)... 2015 Liberty University has received accreditation for ... from the Council for Accreditation of Counseling & Related ... Center for Counseling & Family Studies , is under ... university’s new School of Behavioral Sciences. Prior to the formation ...
(Date:1/22/2015)... Chemo Duck Program is pleased to announce the release of the ... with cancer. The Chemo Duck App, available on iTunes for use ... to help children of all ages living with cancer adjust to ... entertained, educated and at ease while waiting for clinic visits or ...
(Date:1/22/2015)... is a famous wedding dress company offering many trendy designs. ... Facebook, Twitter, and Pinterest. The fans will have an opportunity ... every week. , Moreover, the company has extended its 2015 ... homepage for more information. , Angelweddingdress is a ...
(Date:1/22/2015)... Florida (PRWEB) January 22, 2015 Juvent ... today at the 2015 PGA Merchandise Show to bestow ... and incredible female amateur golfer, Arlene McKitrick. The award ... female amateur golf tournament win. She won her first ...
(Date:1/22/2015)... 2015 For over 20 years, Dr. David Cruz ... Vista area has treated just about every type of injury ... And for those same twenty-plus years, the team at ... injuries with the best possible doctor. With the combined ...
Breaking Medicine News(10 mins):Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2
... boosted physical, mental scores, study finds , , FRIDAY, March ... poor families boosts children,s physical and mental development, a ... of California, Berkeley found that children in low-income families ... from a government-run conditional cash transfer program were taller, ...
... NEW YORK, March 7 Four out of ... dietary supplement every day, according to the,Institute of ... errors are made due to handwritten prescriptions. These ... drug interactions and,allergic reactions., See video ...
... teaching at ... the Medical Center, COLUMBUS, Ohio, March 7 ... last six years accounting,for nearly 50 percent of the region,s net employment ... jobs, says an economic,impact report released today by the Columbus Chamber of ...
... could enable doctors to rule out tuberculosis (TB) infection ... study published this week in the journal Annals of ... College London and the University of Oxford, shows that ... tuberculosis with 99% accuracy when using the new blood ...
... Dr. Lin Mei, chief of developmental neurobiology at the ... Scholar in Neuroscience, has received the 2008 Mathilde Solowey ... administered by Foundation for Advanced Education in the Sciences, ... that is cutting edge, translational and of broad importance. ...
... wont run into grandparents at your local tanning salon? ... a recent health survey of American adults suggests that while ... many as 10 percent of those between 50 and 64 ... 65 tanned indoors. , Researchers at Fox Chase Cancer Center ...
Cached Medicine News:Health News:Government Assistance Linked to Better Child Development 2Health News:Chamber Analysis Shows OSU Medical Center Leads Area Job Growth 2Health News:Chamber Analysis Shows OSU Medical Center Leads Area Job Growth 3Health News:New TB test means quicker and easier diagnosis for patients 2Health News:New TB test means quicker and easier diagnosis for patients 3Health News:Dr. Mei receives 2008 Mathilde Solowey Lecture Award in Neurosciences 2Health News:Dr. Mei receives 2008 Mathilde Solowey Lecture Award in Neurosciences 3Health News:Teenage girls aren't the only ones who tan indoors -- older adults do so as well 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: